US 12,351,572 B2
Substituted 1,2,4-triazoles as TYK2 inhibitors
Bohan Jin, San Francisco, CA (US); Qing Dong, San Francisco, CA (US); Gene Hung, San Francisco, CA (US); and Stephen W. Kaldor, San Francisco, CA (US)
Assigned to Alumis Inc., San Francisco, CA (US)
Filed by Alumis Inc., San Francisco, CA (US)
Filed on Jun. 15, 2023, as Appl. No. 18/335,262.
Application 18/335,262 is a continuation of application No. 17/713,646, filed on Apr. 5, 2022, granted, now 12,060,343.
Application 18/335,262 is a continuation of application No. 17/891,817, filed on Aug. 19, 2022, granted, now 11,731,956.
Application 17/713,646 is a continuation of application No. 17/713,646, filed on Apr. 5, 2022, granted, now 12,060,343.
Application 17/713,646 is a continuation of application No. 17/243,508, filed on Apr. 28, 2021, granted, now 12,006,306.
Application 17/243,508 is a continuation of application No. 16/938,183, filed on Jul. 24, 2020, granted, now 11,053,219, issued on Jul. 6, 2021.
Application 16/938,183 is a continuation of application No. PCT/US2019/057485, filed on Oct. 22, 2019.
Claims priority of provisional application 62/907,354, filed on Sep. 27, 2019.
Claims priority of provisional application 62/893,721, filed on Aug. 29, 2019.
Claims priority of provisional application 62/875,449, filed on Jul. 17, 2019.
Claims priority of provisional application 62/839,459, filed on Apr. 26, 2019.
Claims priority of provisional application 62/756,942, filed on Nov. 7, 2018.
Claims priority of provisional application 62/749,003, filed on Oct. 22, 2018.
Prior Publication US 2023/0391751 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/44 (2006.01); C07D 213/72 (2006.01); C07D 249/08 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01)
CPC C07D 401/14 (2013.01) [C07D 401/12 (2013.01); C07D 403/12 (2013.01)] 7 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
2. A pharmaceutical composition comprising: a pharmaceutically acceptable excipient, and a compound of claim 1 or a pharmaceutically acceptable salt thereof.